Brief: Cynata Says Expanded MEND Clinical Trial In COVID-19 And Respiratory Failure
29/03/2021 13:12
March 29 (Reuters) - Cynata Therapeutics Ltd CYP.AX :
* CYNATA EXPANDS MEND CLINICAL TRIAL IN COVID-19 AND
RESPIRATORY
FAILURE
* CYNATA - EXPANSION TO ENABLE RECRUITMENT OF PATIENTS WITH
RESPIRATORY FAILURE ARISING FROM OTHER CAUSES, WITH COVID-19 NO
LONGER A REQUIREMENT
Source text for Eikon: ID:nGNX7CJXj4
Further company coverage: CYP.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cynata Therapeutics
See all newsBrief: Cynata Therapeutics Says Firm Commitments Received To Raise Further A$550,000 Via Placement
Brief: Cynata Therapeutics Enters Consultancy Agreement With LIR Bio Advisory
Brief: Cynata Therapeutics Establishes Share Sale Facility For Unmarketable Parcel Holders
Brief: Cynata Therapeutics Terminates Of At-The-Market Subscription Deed
Brief: Cynata Therapeutics Posts FY2026 Loss From Ordinary Activities After Tax A$9.1 Million